An observational study in Ovarian Neoplasms, Breast Neoplasms and Colorectal Neoplasms, sponsored by Medical University of Vienna. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Ovarian Neoplasms with a site in Austria — 12 open to participants now, 15 under way, 7 of them phase 3. Ovarian Neoplasms · Austria.
Among the 65 studies in Ovarian Neoplasms with a site in Austria, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2003, is one of 13 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 28th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →12 of the 65 studies in Ovarian Neoplasms with a site in Austria are open now. Recruiting first, the newest first:
AbbVie · Sites in Austria
Ages 18+ · Women only
Genmab · Sites in Austria, United States, Australia and 13 more countries
Ages 18+ · Women only
Merck Sharp & Dohme LLC · Sites in Austria, United States, Argentina and 27 more countries
Ages 18+ · Women only
Eli Lilly and Company · Sites in Austria, United States, Australia and 24 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Austria, United States, Argentina and 26 more countries
Ages 18+ · Women only
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 33
First in 1995; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 574 across the 51 interventional studies, 500 across the 13 observational. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 65 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 6 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Ovarian Neoplasms with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01789229Medical University of ViennaEstablishment of a Tumor Bank for Tissue Samples | 2026-12 |
| NCT01763125Medical University of ViennaEstablishment of a Tumor Bank for Blood Samples | 2026-12 |
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Ovarian Neoplasms with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Establishment of a tumor bank, consisting of tissue samples of tumor patients (benign and malign tumors) and healthy people as controls. The tissue samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tissue tumor bank.
This tumor bank for tissue samples, together with our tumorbank for blood samples (NCT01763125) combined constitute the entity "Tumorbank".
Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of "translational oncology" will only increase in the future -"From bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient.
Its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research.
The aim of this tumor bank is to consist of biological samples (together with a blood bank - see NCT01763125) and isolates of tumor patients and healthy people as controls. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. The content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).
Male and female patients/people. Minimum age 18 years Characteristics: Recruited at the Medical University Vienna or at one of the facilities cooperating with the Vienna Med. University
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who have one of the Neoplasms stated above under "conditions".
Other: Tumor tissue collection · Other: Sampling of ascites and pleural effusion · Other: Collecting urine samples · Other: Collecting saliva sample · Other: Collecting sputum · Other: Collecting stool samples · Other: Lavage/Irrigation
Patients with a benign tumor or an inflammatory disease - to be matched by age.
Other: Tumor tissue collection · Other: Sampling of ascites and pleural effusion · Other: Collecting urine samples · Other: Collecting saliva sample · Other: Collecting sputum · Other: Collecting stool samples · Other: Lavage/Irrigation
People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
Other: Collecting urine samples · Other: Collecting saliva sample · Other: Collecting sputum · Other: Collecting stool samples · Other: Lavage/Irrigation
Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon. Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis. Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger.
Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
Patient is asked to give a urine sample. Urine is collected in urine beaker.
Saliva sample is collected by spatula from the mouth cavity of the patient.
Patient is asked to produce sputum into a 50ml lab tube.
Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.
Time frame: 14 years
Not enrolling at this site.
Not enrolling at this site.
The record gives a start of Sep 2003, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →